Rapine30 mg

Rapine 30 mg Tablets are indicated for the treatment of major depressive disorder (MDD).

Atypical anti-depressant drugs

Rapine 30 mg has clinically significant drug-drug interactions with Monoamine Oxidase Inhibitors (MAOI) & other serotonergic drugs such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St. John's wort. Rapine 30 mg may interrupt the metabolism or activity of Carbamazepine, Phenytoin or Cimetidine. Patient should avoid Alcohol & Diazepam while taking Rapine 30 mg.

The most common side effects of Rapine 30 mg are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc.

Rapine 30 mg Should not be used during pregnancy and lactation.

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Patients who are to receive Rapine 30 mg should be warned about the risk of developing agranulocytosis. Rapine 30 mg may impair judgment, thinking, and particularly, motor skills, because of its prominent sedative effect. Clinically significant ALT (SGPT) elevations (≥3 times the upper limit of the normal range) may occur.

Symptoms: Disorientation, drowsiness, impaired memory, tachycardia. Management: Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac functions. General supportive and symptomatic measures are also recommended. Do not induce emesis. Gastric lavage may be used if done soon after ingestion, or in symptomatic patients. Administer activated charcoal. No specific antidotes are known.

Keep away from light and moisture. Store below 30º C. Keep all medicine out of the reach of children.

Atypical anti-depressant drugs

Pharmacodynamics: The mechanism of action of Rapine 30 mg as with other drugs effective in the treatment of major depressive disorder is unknown. Evidence gathered in preclinical studies suggests that Rapine 30 mg enhances central noradrenergic and serotonergic activity. These studies have shown that Rapine 30 mg acts as an antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Rapine 30 mg is a potent antagonist of 5- HT2 and 5-HT3 receptors. Rapine 30 mg has no significant affinity for the 5-HT1A and 5-HT1B receptors. Rapine 30 mg is a potent antagonist of histamine (H1) receptors, a property that may explain its prominent sedative effects. Rapine 30 mg is a moderate peripheral α1-adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use. Rapine 30 mg is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use.Pharmacokinetics: After oral administration of Rapine 30 mg tablets, the active constituent Rapine 30 mg is rapidly and well-absorbed, reaching peak plasma levels after about 2 hours. Binding of Rapine 30 mg to plasma proteins is approximately 85%. The mean half-life of elimination is 20-40 hours; (26 hours in males, 37 hours in females). The half-life of elimination is sufficient to justify once-a-day dosing. Rapine 30 mg displays linear pharmacokinetics within the recommended dose range. Rapine 30 mg is extensively metabolized and eliminated via the urine and faeces four days. Major pathways of biotransformation are demethylation and oxidation followed by conjugation.

Pregnancy Category-C. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Rapine 30 mg therapy. Patients should be advised to notify their physician if they are breastfeeding an infant.